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Abstract
Dyslipidemia is a well-established risk factor for cardiovascular disease, the main cause of death 
worldwide. Blood lipid profiles are patterned by both genetic and environmental factors. In recent 
years, epigenetics has emerged as a paradigm that unifies these influences. In this review, we have 
summarized the latest evidence implicating epigenetic mechanisms—DNA methylation, histone 
modification, and regulation by RNAs—in lipid homeostasis. Key findings have emerged in a 
number of novel epigenetic loci located in biologically plausible genes (e.g. CPT1A, ABCG1, 
SREBF1, and others), as well as microRNA-33a/b. Evidence from animal and cell culture models 
suggests a complex interplay between different classes of epigenetic processes in the lipid-related 
genomic regions. While epigenetic findings hold the potential to explain the interindividual 
variability in lipid profiles as well as the underlying mechanisms, they have yet to be translated 
into effective therapies for dyslipidemia.
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Introduction
Elevated plasma triglycerides (TGs), alone or in conjunction with increased low-density 
lipoprotein (LDL) and decreased high-density lipoprotein (HDL) cholesterol, are well-
documented risk factors for cardiovascular disease [1]. Despite high estimates of heritability 
(48% and above [2]) and limited influence of shared environment, known genetic variants 
explain approximately 10% of the observed variance in plasma lipids [3, 4]. Recent evidence 
shows that a significant proportion of the remaining genetic variability may be attributable to 
epigenetic processes, defined as heritable, non-sequence-dependent changes in gene 
expression [5].
In contrast to sequence polymorphisms, epigenetic variation is specific, dynamic (and even 
reversible throughout the lifecourse), and mechanistically diverse. These characteristics both 
make it a lucrative target and pose translational challenges. For example, the cell and tissue 
specificity enhances pathophysiologic relevance, but often complicates measurements as 
probing some organs implicated in lipid metabolism—e.g. the liver—is invasive and costly. 
While several studies have demonstrated conservation of epigenetic patterns and validated 
the use of easily accessible tissues such as blood for epigenetic measurements [6], the 
variants that remain tissue-specific are more likely to be causally related to disease risk. 
Furthermore, the reversibility of epigenetic marks raises the issue of reverse causation: is the 
change in the epigenetic profile a cause or a consequence of the phenotype? Despite 
plausible mechanisms for either possibility in the lipid context, current evidence for DNA 
methylation supports only the latter path, wherein lipids prime circulating immune cells to 
regulate their own synthesis [7]. Finally, the sheer variety of biochemical modifications 
involved in epigenetic inheritance creates a daunting yet promising ground for 
investigations. Known processes that contribute to epigenetic effects are chromatin 
remodeling via DNA methylation and histone modification, RNA-based mechanisms, 
structural inheritance (or three-dimensional templating), and self-sustaining metabolic loops 
(reviewed in [8]). Currently available evidence supports the diverse roles of DNA 
methylation, histone modification, and regulatory RNAs in the setting of dyslipidemia; these 
three classes of epigenetic mechanisms will constitute the main focus of this review.
DNA methylation
DNA methylation, which refers to the addition of a methyl group to the DNA molecule, is 
by far the most studied epigenetic process with respect to human lipid traits, with several 
large-scale epigenome-wide studies enabled by cost-effective methylation array technology. 
In human somatic cells, DNA methylation occurs at approximately 70%–80% of cytosine-
phosphase-guanine (CpG) sites throughout the genome [9] and can be influenced by both 
DNA sequence and environmental inputs. Depending on the location of the CpG site and the 
physiologic context, methylation can down- or upregulate gene expression via a variety of 
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mechanisms, including but not limited to effects on chromatin conformation, alternative 
splicing, and mRNA transcript levels (reviewed in [10]).
The emerging body of evidence linking lipids and DNA methylation includes three 
categories: 1) cross-sectional studies fasting lipids; 2) epigenetic predictors or correlates of 
lipid changes following a dietary or a pharmaceutical intervention; and 3) transgenerational 
effects of maternal genotype and/or environment on offspring lipid levels. Fasting lipids are 
a standard measurement in many epidemiologic cohorts and most early epigenetic studies 
have focused on candidate gene or repetitive element methylation (Table 1). The most robust 
and interesting targets, however, have arisen from epigenome-wide investigations of fasting 
lipids (Table 2). The earliest such study reported two differentially methylated sites in 
TNNT1 using the Illumina 27K technology in participants with familial 
hypercholesterolemia [11]. However, these findings were not replicated in subsequent 
studies using the higher-resolution Illumina 450K chip. Instead, the next wave of studies 
pointed to methylation in the first intron of CPT1A, which encodes the liver isoform of 
carnitine palmitoyltransferase 1 (CPT1), a key enzyme in the fatty acid biosynthesis pathway 
[12]. A deficiency in CPT1 impairs the carnitine-dependent transport of long-chain fatty 
acids into the mitochondria, lowering the rate of beta-oxidation [13] with profoundly 
adverse metabolic effects [14]. In the first published epigenome-wide study of fasting lipids 
using the 450K array, Irvin et al. have reported a robust inverse association between CPT1A 
methylation and expression as well as fasting TGs and very low density lipoprotein (VLDL) 
cholesterol [12]. Methylation at the top CPT1A locus explained 12% of TG variation in the 
discovery cohort (Genetics of Lipid Lowering Drugs and Diet Network (GOLDN), CD4+ 
lymphocytes, n=991) and 6% in the replication cohort (Framingham Heart Study, whole 
blood, n=1261) [12]. Subsequent studies have replicated the observed association with lipids 
[7, 15, 16] and lipoprotein subfraction profiles [17], as well as linked CPT1A methylation 
with obesity traits [18, 19], metabolic syndrome [20], and hypertriglyceridemic waist [21] in 
diverse populations. Interestingly, CPT1A loci were also shown to be differentially 
methylated in Dutch Hunger Winter survivors exposed to famine in utero, associating with 
both birth weight and serum LDL cholesterol levels later in life [22] and providing a 
possible mechanism for the well-known adverse metabolic sequelae of prenatal malnutrition.
Another robust association with multiple phenotypes, namely increased TGs and markers of 
insulin resistance and decreased HDL-cholesterol, was reported in multiple cohorts and 
tissues for a methylation locus in ABCG1 [15, 23]. Similarly to the CPT1A finding, the 
observed association exhibits strong biological plausibility because the product of ABCG1 
plays a central role in cholesterol and phospholipid reflux [24]. The differential methylation 
pattern of ABCG1 with respect to HDL cholesterol and TGs, potentially mediated by 
ABCG1 expression, was observed in both blood and adipose tissue but not skin, and 
putatively associated with prevalent myocardial infarction [15]. The same epigenome-wide 
study also identified and replicated associations between TGs and methylation loci in 
MIR33B/SREBF1 and an intergenic region on chromosome 10, and between LDL 
cholesterol and a locus in TNIP1 [15]. SREBF1, which contains intronic microRNA 
(miR)33b, and SREBF2 encode transcription factors that regulate fatty acid and cholesterol 
metabolism [25]. Notably, miR33b represses the transcription of both CPT1A and ABCG1 
(reviewed in [15]), demonstrating the interplay between 1) genes that exhibit differential 
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methylation in dyslipidemia and 2) various classes of epigenetic processes, in particular 
methylation and RNA-based mechanisms. The first type of interplay is also illustrated by the 
connection between the LDL-cholesterol locus in TNIP1, the gene encoding a protein that 
interacts with tumor necrosis factor alpha, and ABCG1 via the peroxisome proliferator-
activated receptors (reviewed in [15]).
Most reports of associations between methylation variants and lipid phenotypes in humans 
came from cross-sectional studies, which preclude any inferences of temporality and thus 
causality. The few dynamic studies of DNA methylation have yielded mixed results. In the 
GOLDN cohort, there was no evidence that the changes in lipids that occur over the 3-week 
long treatment with fenofibrate correlate with either epigenome-wide or candidate gene 
methylation changes [26]. In the same study population, however, TG response to a high-fat 
meal intervention was linked to differential methylation of CPT1A, APOA5, LPP, SREBF1, 
and ABCG1 [unpublished], which collectively explained approximately 15% of the 
phenotypic variance; however, the association was attenuated after adjustment for fasting 
levels. Nevertheless, these epigenetic markers—three of which overlap with known 
methylation correlates of fasting lipids— merit follow-up studies on the basis of their 
functional plausibility. Other prospective evidence comes from transgenerational studies that 
highlight the importance of the intrauterine environment for the risk of impaired metabolism 
in the offspring [27, 28]. These studies, however, are few and limited by the lack of 
mechanistic insights [28], repeated methylation measurements throughout the life course 
[22], or both.
The best evidence of causal relationships between lipids and DNA methylation comes from 
a recent epigenomic study of lipids in whole blood from 3296 individuals that employed 
stepwise Mendelian randomization, an instrumental variable approach which uses genotype 
at a validated locus (e.g. a lipids genetic risk score) as a randomly assigned proxy for the 
phenotype itself [7]. The advantages of Mendelian randomization, and particularly Egger 
regression (MR-Egger) as implemented by Dekkers et al., include control for measured and 
unmeasured confounding and pleiotropy [29]. Using the MR-Egger approach, this largest 
epigenome-wide investigation of lipids to date has generated compelling evidence that lipids 
influence differential methylation in CPT1A, SREBF1 (TGs), ABCG1 (TGs, HDL 
cholesterol), and DHCR24 (LDL cholesterol), but not vice versa [7]. Of the four genes 
causally implicated by MR-Egger, only DHCR24 had not been previously discussed in 
cross-sectional studies. The DHCR24 gene is nevertheless highly relevant because it encodes 
the enzyme catalyzing the terminal step in the cholesterol biosynthesis pathway [30], and is 
regulated by sterol regulatory element binding proteins such as those encoded by SREBF1 
[31]. The conclusions of the study, which support the causal effects of lipids on methylation 
at several biologically plausible loci, are consistent with prior evidence of cholesterol 
inhibiting its own synthesis—possibly via epigenetic priming that occurs prior to tissue 
differentiation [32, 33, cited in 7]. Future studies would benefit from interrogating other 
germane tissues, e.g. samples from adipose or hepatic biopsies, to identify a comprehensive 
methylation signature for dyslipidemia. Finally, it is worth remarking that of all the genes 
reported to present differential methylation associated with lipid traits, only some have been 
identified in genome-wide association studies to be associated with these traits (e.g. CPT1A, 
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MYLIP, and APOA5), highlighting the potential of epigenome-wide association studies to 
explain the “missing heritability” of lipid metabolism [34, 35].
Histone modifications
Post-translational modifications of diverse amino acid residues on histones, which include 
acetylation, methylation, and phosphorylation, represent another class of epigenetic 
mechanisms governing gene expression [36]. While chromatin immunoprecipitation (ChIP) 
methods can be used to characterize histone modifications in selected regions (via 
quantitative PCR) or on the epigenome-wide scale (via arrays or deep sequencing), most 
existing studies of lipid phenotypes use this technology for follow-up of DNA sequence or 
methylation findings rather than discovery. For example, functional annotation of 95 known 
lipid SNPs [34] with data from the Encyclopedia of DNA Elements (ENCODE) project 
found enrichment for histone marks associated with transcription regulation, particularly in 
hepatic cells [37]. A similar analysis of SNPs in GALNT2, an HDL cholesterol locus, found 
multiple instances of overlap with histone modification peaks in the liver [38]. This 
approach may be especially promising in DNA methylation studies due to the cross-talk 
between enzymes involved in both histone and DNA modifications [39]. The 
interdependency of epigenetic processes is observed in all four genes harboring lipid-
regulated methylation loci, as the expression of DHCR24 [40], CPT1A [41], ABCG1 [42], 
and SREBF isoforms [43] has previously been correlated with histone modifications in 
human cells or animal models.
In addition to functional studies of histone marks in known lipid loci, ChIP technology 
offers the potential to identify novel epigenetic correlates of metabolic phenotypes, although 
these studies are yet to be implemented on a large scale in humans. In Japanese macaques, in 
utero exposure to a high-fat calorie-dense maternal diet has been shown to alter histone 
acetylation patterns, putatively correlated with expression at several genes of interest, e.g. 
Npas2 [44]. In humans, disrupted expression of circadian genes such as NPAS2 has been 
extensively linked to abnormal metabolic phenotypes, specifically dyslipidemia (reviewed in 
[45]), yet the underlying mechanisms are not well understood; epigenetic processes such as 
post-translational histone acetylation warrant future studies as potential mediators.
Any discussion of histone modifications in the context of lipids would be remiss to exclude 
statins, a broad class of drugs successfully used to lower LDL cholesterol levels by 
inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG Co-A). In addition to their 
primary lipid-lowering action, statins also inhibit histone deacetylases (HDACs [46]), 
notably HDAC2 in atherosclerotic plaques of human coronary arteries, and modulate 
oxidized LDL-induced expression of inflammatory genes [47]. While these mechanistic 
insights have generated enthusiasm, particularly in oncology [48], they have yet to be 
translated into clinical breakthroughs.
RNA-based mechanisms
A number of non-coding RNAs, including small (<200 nucleotides) and long (≥200 
nucleotides) non-coding RNAs, can indirectly regulate gene expression via interactions with 
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canonical epigenetic processes such as histone acetylation/methylation or DNA methylation, 
as well as directly by targeting mRNA [49]. The majority of research on their role in lipid 
homeostasis to date has focused on microRNAs (miRNAs), which have been shown to 
control lipoprotein levels in plasma (summarized in [50]) through several mechanisms. A 
useful example is the well-studied miR-33a/b, previously discussed in the context of DNA 
methylation findings. In experimental models, miR-33 isoforms decreased hepatic 
biogenesis of HDL cholesterol and attenuated cellular cholesterol efflux in an ABCA1 and 
ABCG1 dependent manner [51]. Additional evidence suggests that miR-33 inhibition 
promotes regression of atherosclerotic plaques by affecting both lipid transport [52] and 
inflammation [53]. Similar positive effects on plasma lipid profiles were achieved in 
nonhuman primates [54], raising the therapeutic relevance of these discoveries. On the other 
hand, miR-33 knockout mice fed a high-fat diet also exhibited increased total plasma 
cholesterol, obesity, insulin resistance, and fatty liver, mediated by interactions with hepatic 
SREBP-1 [25]. These deleterious metabolic effects, however, were not observed with 
miR-33 inhibition rather than genetic deletion [55]. MiR-33 also has other targets, including 
CPT1A and p53 (reviewed in [56]), although the current understanding of such disparate 
effects is rather limited. The miR-33 story highlights the translational promise of small 
regulatory RNAs in dyslipidemia and urges caution in regard to potential pleiotropic effects 
of any miR-based therapies.
The role of long noncoding RNAs (lncRNAs) in lipid homeostasis is also coming to sharper 
focus, with multiple in vitro studies implicating lncRNAs in hepatic lipid metabolism and 
adipogenesis (reviewed in [57]). For example, a recent study identified LeXis (liver-
expressed LXR-induced sequence), a lncRNA located in close proximity to Abca1 in the 
murine genome, as a mediator of the liver X receptor-induced cholesterol efflux and 
simultaneous decrease in cholesterol synthesis [58]. However, because lncRNAs are not as 
highly evolutionarily conserved as miRNAs [57], the enthusiasm for their potential 
therapeutic use must remain tempered until proof of concept from human studies. Overall, 
RNA-based processes represent an important frontier in epigenetic studies of lipids, and 
future large-scale human studies are poised to take advantage of shotgun transcriptomics 
technologies (RNASeq) to further explore these mechanisms.
Conclusion
The epigenetic signature of dyslipidemia is complex, spanning multiple genomic regions, 
biochemical processes, and phenotypes. The relationship between lipids and epigenetic 
markers is dynamic and likely bidirectional; while lipid levels pattern methylation of key 
relevant genes (CPT1A, ABCG1, SREBF1, DHCR24), other epigenetic processes (e.g. 
regulation of gene expression by miR-33) are likely a cause rather than a consequence of 
altered lipid profiles. The genomic regions implicated in dyslipidemia often harbor more 
than one type of epigenetic change, as illustrated by the relationship between miR-33 and 
methylation findings in ABCG1 and SREBF1, and epigenetic effects of each variant can be 
pleiotropic. Future efforts aiming to realize the nontrivial translational potential of 
epigenetic findings in dyslipidemia would benefit from heeding the intricate variability of 
the observed patterns across time, tissue, and physiologic context.
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Table 1
Selected studies of candidate gene and repetitive element methylation and lipid phenotypes.
Repetitive Element Methylation Studies
Reference Population (tissue) N Phenotype(s): associated changes in
global methylation
[59] European (whole blood) 738 HDL-c: hypomethylation
[60] European (whole blood) 228 TC, LDL-c, TG, HDL-c: hypomethylation
[61] Samoan (whole blood) 355 LDL-c, HDL-c: hypomethylation
Candidate Gene Studies
Reference Population (tissue) N Phenotype(s): associated gene
[62] Canadian with severe obesity
(whole blood, adipose tissue)
73 LDL-c: LEP, ADIPOQ
[63] Chinese children (whole blood) 98 LDL-c, TG, HDL-c: FAIM2
[64] European American (CD4+ T
cells)
993 TC, LDL-c: APOE
[65] European children with obesity
(whole blood)
85 TG: IGF2
[66], [67] French Canadian with untreated
familial hypercholesterolemia
(whole blood)
98 LDL-c, HDL-c, TG: ABCG1, LIPC, PLTP
HDL-c: ABCA1
[68] European American (whole
blood)
517 TC, LDL-c: FABP3
[69] Chinese with diabetes and healthy
controls (peripheral blood
mononuclear cells)
47 TG: MCP1
[70] Canadian women with severe
obesity (visceral adipose tissue)
92 HDL-c: DPP4
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Table 2
Epigenome-wide studies of DNA methylation and lipid phenotypes.
Reference Array Population (tissue) N Phenotype(s): Top associated
CpG (gene)
[11] Illumina 27K French Canadian with
familial
hypercholesterolemia
(whole blood)
Discovery: 21
Replication: 70 (untreated) and
178 (treated with lipid-lowering
drugs)
HDL-c: cg07189381 (TNNT1)
[12] Illumina 450K European American
(CD4+ T cells)
Discovery: 663
Replication: 331
VLDL and LDL subfraction
parameters: cg00574958
(CPT1A)
[17] Illumina 450K European American
(CD4+ T cells)
Discovery: 991
Replication: 2711
VLDL-c and TG: cg00574958
(CPT1A)
[15] Illumina 450K European (whole
blood, adipose tissue,
skin)
Discovery (whole blood): 1776
Replication (whole blood): 971
Replication (adipose): 634
Replication (skin): 395
LDL-c: cg22178392 (TNIP1),
TG and HDL-c: cg06500161
(ABCG1)
[26] Illumina 450K European American
(CD4+ T cells)
443 Change in lipids following
fenofibrate treatment: no
significant findings
[22] Reduced
Representation
Bisulfite
Sequencing
European, survivors of
the Dutch Hunger
Winter and sibling
controls (whole blood)
120 LDL-C: differentially
methylated region in CPT1A
[7] Illumina 450K European (whole
blood)
3296 LDL-c: cg27168858
(DHCR24), TG: cg11024682
(SREBF1), cg06500161/
cg27243685 (ABCG1) and
cg00574958/ cg17058475
(CPT1A), HDL-c: cg06500161/
cg27243685 (ABCG1)
Curr Cardiovasc Risk Rep. Author manuscript; available in PMC 2017 October 01.
